Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) told investors that revenue growth accelerated in its second half and has guided for a further step-up in the current year as Grassmuno enters its first full peak treatment season.
Second-half revenue is expected to reach £23.6 million, up more than 12% on a reported basis from £21 million a year earlier. That compares with 7% growth in the first half.
Full-year revenue is forecast at £59.9 million, 9% higher than the previous year’s £55 million. Constant-currency growth was around 5%, including increases of more than 4% in Germany and 12% in Spain.
The allergy immunotherapy specialist expects double-digit revenue growth in the year to June 2027, supported by Grassmuno’s first full high season and the end of Germany’s transition away from unregistered products under the TAV programme.
Cash stood at £24.2 million at the year-end, compared with £12.8 million a year earlier, after the company repaid its shareholder loans and drew down a new £40 million secured facility from Hayfin.
